Related Experiment Video
Updated: Apr 23, 2026
Chromosome Screening of Human Preimplantation Embryos by Using Spent Culture Medium: Sample Collection and Chromosomal Ploidy Analysis
Published on: September 7, 2021
A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome
Brandon S Walker1, Brian R Jackson, Danielle LaGrave
1Department of Pathology and ARUP Laboratories, School of Medicine, University of Utah, Salt Lake City, UT, USA.
Objective:
The aim of this article is to determine the cost effectiveness of cell free DNA (cfDNA) as a replacement for integrated screening using a societal cost perspective.
Method:
This study used Monte-Carlo simulation with one-way and probabilistic sensitivity analysis.
Results:
Cell free DNA is more effective and less costly than integrated screening. The incremental cost-effectiveness ratio for cfDNA relative to the integrated test was -$277 955 per case detected (95th percent confidence interval -$881 882 to $532 785).
Conclusion:
Cell free DNA screening is a cost-effective replacement for maternal serum screening when the lifetime costs of Down syndrome live births are considered. The adoption of cfDNA screening would save approximately $277 955 for each additional case detected over integrated screening.
More Related Videos
09:30Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
08:08Cell-based Assay Protocol for the Prognostic Prediction of Idiopathic Scoliosis Using Cellular Dielectric Spectroscopy
Published on: October 16, 2013